JP2012019790A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012019790A5 JP2012019790A5 JP2011178553A JP2011178553A JP2012019790A5 JP 2012019790 A5 JP2012019790 A5 JP 2012019790A5 JP 2011178553 A JP2011178553 A JP 2011178553A JP 2011178553 A JP2011178553 A JP 2011178553A JP 2012019790 A5 JP2012019790 A5 JP 2012019790A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- flt4
- tissue
- bound
- detecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
本発明は腫瘍性疾患の状態のスクリーニング方法であって、(a)腫瘍性疾患の状態にあると推定される哺乳類生物由来の組織と、Flt4受容体チロシンキナーゼと特異的に結合する抗体または抗体断片を含んでなる組成物とを接触させ;(b)哺乳類生物において細胞に結合した抗体または抗体断片を検出し;さらに(c)哺乳類生物において細胞に結合した抗体の量または分布から腫瘍性疾患をスクリーニングする工程を含んでなる方法にさらに向けられる。本明細書において記載されるようにFlt4(通常血管構造においては検出されないか、またはかろうじて検出可能である)は少なくともいくつかの腫瘍の血管構造で強く染色される。よって、1つの具体例においてスクリーニング工程では血管内皮細胞に結合した抗体または抗体断片の検出は腫瘍性疾患の存在に相関している。この方法での「検出」とは、本明細書において記載されるように相当する正常(健康な)組織で起こるかろうじて検出可能な、または検出されないレベルを有意に上回るレベルにおける検出を意味する。かかる特徴的な発現は健康な生物由来の組織を用いて行う対照との比較により確認できる。特に哺乳類組織の腫瘍のスクリーニングを意図する。上述のように、かかる方法の実施は血管内皮マーカーと特異的に結合する第2の化合物を哺乳類に投与することによりさらに容易になり、そこで検出工程は新生血管内皮細胞と結合した第1および第2の化合物を検出することを含んでなる。
Claims (12)
- 腫瘍性疾患の状態のスクリーニング方法であって、
(a)腫瘍性疾患の状態にあると疑われる哺乳類生物由来の組織と、Flt4受容体チロシンキナーゼと特異的に結合する化合物を含んでなる組成物とをイン・ビトロで接触させること;
(b)該組織において細胞に結合した化合物を検出すること;および
(c)哺乳類生物において細胞に結合した化合物の量または分布から腫瘍性疾患をスクリーニングすること(ここで、血管内皮細胞に結合した化合物の検出が、腫瘍性疾患の存在と相関している)
を含んでなる、方法。 - 新生血管内皮細胞の変化によって特徴づけられる疾病のスクリーニング方法であって、
(a)新生血管内皮細胞の変化によって特徴づけられる病状にあると疑われる哺乳類生物由来の組織サンプルを、その生物の細胞によって発現されたFlt4受容体キナーゼと特異的に結合する化合物を含んでなる組成物に曝すこと;および
(b)組織サンプルにおいて化合物の存在、量または分布を検出することによって疾病をスクリーニングすること(ここで、新生血管内皮細胞に結合した化合物の検出が、生物における腫瘍性疾患の存在と相関している)
を含んでなる、方法。 - 哺乳類生物の新生血管内皮細胞を検出する方法であって、
(a)哺乳類生物由来の組織と、Flt4受容体チロシンキナーゼと特異的に結合する化合物を含んでなる組成物とをイン・ビトロで接触させること;および
(b)組織において、新生血管内皮細胞と結合した化合物を検出し、それによりその哺乳類生物における新生血管内皮細胞を検出すること
を含んでなる、方法。 - 化合物が、
(a)抗Flt4抗体またはその抗原結合断片;
(b)抗Flt4抗体の抗原結合断片を含んでなるポリペプチド;および
(c)Flt4リガンドまたはそのFlt4結合断片を含んでなるポリペプチド
からなる群から選択されるポリペプチドを含んでなる、請求項1〜3のいずれか一項に記載の方法。 - 化合物が、Flt4リガンドまたはそのFlt4結合断片であり、Flt4リガンドが、血管内皮増殖因子C(VEGF−C)および血管内皮増殖因子D(VEGF−D)からなる群から選択される、請求項1〜3のいずれか一項に記載の方法。
- 化合物が、抗Flt4抗体である、請求項4に記載の方法。
- 化合物が、検出可能な標識をさらに含んでなる、請求項1〜6のいずれか一項に記載の方法。
- 組織が、哺乳類の組織である、請求項1〜7のいずれか一項に記載の方法。
- 腫瘍性疾患が、乳癌である、請求項8に記載の方法。
- 哺乳類生物が、ヒトである、請求項1〜9のいずれか一項に記載の方法。
- 組織と、血管内皮マーカーと特異的に結合する第2の化合物とを接触させることをさらに含んでなり、かつ、検出工程が、新生血管内皮細胞と結合した化合物および第2の化合物を検出することを含んでなる、請求項3に記載の方法。
- 血管内皮マーカーが、PAL−E、VEGFR−1およびVEGFR−2からなる群から選択される、請求項11に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/169,079 US6824777B1 (en) | 1992-10-09 | 1998-10-09 | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
US09/169,079 | 1998-10-09 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000575533A Division JP4841724B2 (ja) | 1998-10-09 | 1999-10-08 | 腫瘍イメージングおよび抗腫瘍治療の標的としてのFlt4(VERG−3) |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012019790A JP2012019790A (ja) | 2012-02-02 |
JP2012019790A5 true JP2012019790A5 (ja) | 2012-08-23 |
JP5642637B2 JP5642637B2 (ja) | 2014-12-17 |
Family
ID=22614189
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000575533A Expired - Fee Related JP4841724B2 (ja) | 1998-10-09 | 1999-10-08 | 腫瘍イメージングおよび抗腫瘍治療の標的としてのFlt4(VERG−3) |
JP2011000273A Expired - Lifetime JP5784310B2 (ja) | 1998-10-09 | 2011-01-04 | 腫瘍イメージングおよび抗腫瘍治療の標的としてのFlt4(VERG−3) |
JP2011178553A Expired - Fee Related JP5642637B2 (ja) | 1998-10-09 | 2011-08-17 | 腫瘍イメージングおよび抗腫瘍治療の標的としてのFlt4(VERG−3) |
JP2013097900A Pending JP2013209382A (ja) | 1998-10-09 | 2013-05-07 | 腫瘍イメージングおよび抗腫瘍治療の標的としてのFlt4(VERG−3) |
JP2015077656A Pending JP2015157829A (ja) | 1998-10-09 | 2015-04-06 | 腫瘍イメージングおよび抗腫瘍治療の標的としてのFlt4(VERG−3) |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000575533A Expired - Fee Related JP4841724B2 (ja) | 1998-10-09 | 1999-10-08 | 腫瘍イメージングおよび抗腫瘍治療の標的としてのFlt4(VERG−3) |
JP2011000273A Expired - Lifetime JP5784310B2 (ja) | 1998-10-09 | 2011-01-04 | 腫瘍イメージングおよび抗腫瘍治療の標的としてのFlt4(VERG−3) |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013097900A Pending JP2013209382A (ja) | 1998-10-09 | 2013-05-07 | 腫瘍イメージングおよび抗腫瘍治療の標的としてのFlt4(VERG−3) |
JP2015077656A Pending JP2015157829A (ja) | 1998-10-09 | 2015-04-06 | 腫瘍イメージングおよび抗腫瘍治療の標的としてのFlt4(VERG−3) |
Country Status (13)
Country | Link |
---|---|
US (4) | US8444957B2 (ja) |
EP (1) | EP1119371B1 (ja) |
JP (5) | JP4841724B2 (ja) |
CN (1) | CN100340291C (ja) |
AT (1) | ATE489108T1 (ja) |
AU (2) | AU774266B2 (ja) |
CA (1) | CA2345276C (ja) |
DE (1) | DE69942981D1 (ja) |
DK (1) | DK1119371T3 (ja) |
ES (1) | ES2357406T3 (ja) |
NO (1) | NO20011759L (ja) |
NZ (2) | NZ511408A (ja) |
WO (1) | WO2000021560A1 (ja) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6818220B1 (en) | 1994-11-14 | 2004-11-16 | Licentia Ltd. | Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof |
US6361946B1 (en) | 1997-02-05 | 2002-03-26 | Licentia Ltd | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
US7423125B2 (en) | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
ATE242809T1 (de) | 1995-09-08 | 2003-06-15 | Genentech Inc | Vegf-verwandtes protein |
US7125714B2 (en) | 1997-02-05 | 2006-10-24 | Licentia Ltd. | Progenitor cell materials and methods |
DE69942981D1 (de) * | 1998-10-09 | 2011-01-05 | Vegenics Ltd | Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie |
US7223724B1 (en) | 1999-02-08 | 2007-05-29 | Human Genome Sciences, Inc. | Use of vascular endothelial growth factor to treat photoreceptor cells |
EP1553414A1 (en) * | 1999-04-13 | 2005-07-13 | Medarex, Inc. | Methods for the diagnosis and treatment of metastatic prostate tumors |
WO2001062942A2 (en) | 2000-02-25 | 2001-08-30 | Ludwig Institute For Cancer Research | MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAs AND PROTEINS AND SCREENING METHODS FOR MODULATORS |
US7273751B2 (en) | 2000-08-04 | 2007-09-25 | Human Genome Science, Inc. | Vascular endothelial growth factor-2 |
US7611711B2 (en) | 2001-01-17 | 2009-11-03 | Vegenics Limited | VEGFR-3 inhibitor materials and methods |
CN1494552A (zh) | 2001-01-19 | 2004-05-05 | ·��ά��֢�о�Ժ | Flt4(VEGFR-3)作为靶用于肿瘤成像和抗肿瘤治疗 |
US7208582B2 (en) | 2001-04-13 | 2007-04-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US7109165B2 (en) | 2001-05-18 | 2006-09-19 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
JP2005518336A (ja) * | 2001-06-26 | 2005-06-23 | イムクローン システムズ インコーポレイティド | Vegf受容体に結合する二重特異性抗体 |
US20030113324A1 (en) * | 2001-10-01 | 2003-06-19 | Kari Alitalo | Neuropilin/VEGF-C/VEGFR-3 materials and methods |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP1432724A4 (en) * | 2002-02-20 | 2006-02-01 | Sirna Therapeutics Inc | RNA inhibition mediated inhibition of MAP KINASE GENES |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US8003613B2 (en) | 2003-11-17 | 2011-08-23 | University Of Florida Research Foundation, Inc. | Methods and compositions for inducing apoptosis |
ATE452188T1 (de) | 2004-02-10 | 2010-01-15 | Sirna Therapeutics Inc | Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid) |
WO2005087177A2 (en) | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
WO2007022287A2 (en) | 2005-08-15 | 2007-02-22 | Vegenics Limited | Modified vegf and pdgf with improved angiogenic properties |
US7629125B2 (en) | 2006-11-16 | 2009-12-08 | General Electric Company | Sequential analysis of biological samples |
US9201063B2 (en) | 2006-11-16 | 2015-12-01 | General Electric Company | Sequential analysis of biological samples |
US8305579B2 (en) | 2006-11-16 | 2012-11-06 | Thomas Pirrie Treynor | Sequential analysis of biological samples |
US9677125B2 (en) | 2009-10-21 | 2017-06-13 | General Electric Company | Detection of plurality of targets in biological samples |
US9011861B2 (en) | 2010-02-25 | 2015-04-21 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
EP3327125B1 (en) | 2010-10-29 | 2020-08-05 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
EP2911681A1 (en) | 2012-10-26 | 2015-09-02 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis |
CA2901226C (en) | 2013-02-18 | 2020-11-17 | Vegenics Pty Limited | Vascular endothelial growth factor binding proteins |
WO2014182635A1 (en) | 2013-05-08 | 2014-11-13 | Baldwin Megan E | Biomarkers for age-related macular degeneration (amd) |
KR102131370B1 (ko) | 2013-10-18 | 2020-07-08 | 삼성전자주식회사 | Vegf-c에 특이적으로 결합하는 폴리펩타이드 및 그의 용도 |
CN114262683B (zh) * | 2022-03-01 | 2022-06-17 | 中国科学院动物研究所 | 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4652639A (en) | 1982-05-06 | 1987-03-24 | Amgen | Manufacture and expression of structural genes |
US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
US4933294A (en) | 1984-01-30 | 1990-06-12 | Icrf Patents Limited | Method of detecting truncated epidermal growth factor receptors |
NZ223834A (en) | 1987-03-11 | 1990-05-28 | Erba Carlo Spa | Immunoglobulin conjugate of an antibody and idarubicin |
ES2092468T3 (es) | 1988-01-22 | 1996-12-01 | Zymogenetics Inc | Metodos para producir analogos de receptores secretados. |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5198359A (en) | 1989-03-07 | 1993-03-30 | Boehringer Ingelheim International Gmbh | Recombinant protein receptor for il-2 |
CA2057854C (en) | 1989-05-22 | 2000-01-11 | James D. Kelly | Pdgf .alpha.-receptor |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
CA2100559C (en) | 1991-01-31 | 2007-05-22 | David Wolf | Domains of extracellular region of human platelet derived growth factor receptor polypeptides |
US5256766A (en) | 1991-02-19 | 1993-10-26 | The Regents Of The University Of California | Recombinant thrombin receptor and related pharmaceuticals |
EP0536350B1 (en) | 1991-02-22 | 2002-08-07 | American Cyanamid Company | Identification of a novel human receptor tyrosine kinase gene |
US5231001A (en) | 1991-03-14 | 1993-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor |
US5367057A (en) | 1991-04-02 | 1994-11-22 | The Trustees Of Princeton University | Tyrosine kinase receptor flk-2 and fragments thereof |
US5185438A (en) | 1991-04-02 | 1993-02-09 | The Trustees Of Princeton University | Nucleic acids encoding hencatoporetic stem cell receptor flk-2 |
US5270458A (en) | 1991-04-02 | 1993-12-14 | The Trustees Of Princeton University | Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2 |
AU669124B2 (en) | 1991-09-18 | 1996-05-30 | Kyowa Hakko Kirin Co., Ltd. | Process for producing humanized chimera antibody |
CA2127540A1 (en) | 1992-01-09 | 1993-07-22 | Juha Partanen | Tie, a novel endothelial cell receptor tyrosine kinase |
US6331302B1 (en) | 1992-01-22 | 2001-12-18 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
AU3482493A (en) | 1992-01-22 | 1993-09-01 | New England Deaconess Hospital | Novel protein tyrosine kinases |
US5635177A (en) | 1992-01-22 | 1997-06-03 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
US5660827A (en) | 1992-03-05 | 1997-08-26 | Board Of Regents, The University Of Texas System | Antibodies that bind to endoglin |
US5776755A (en) | 1992-10-09 | 1998-07-07 | Helsinki University Licensing, Ltd. | FLT4, a receptor tyrosine kinase |
US6824777B1 (en) | 1992-10-09 | 2004-11-30 | Licentia Ltd. | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
EP1167384B1 (en) | 1992-10-28 | 2006-12-13 | Genentech, Inc. | HVEGF Receptor as Vascular endothelial cell growth factor antagonists |
US5712395A (en) | 1992-11-13 | 1998-01-27 | Yissum Research Development Corp. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
US5763441A (en) | 1992-11-13 | 1998-06-09 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
DE4337197C1 (de) | 1993-10-30 | 1994-08-25 | Biotest Pharma Gmbh | Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
DK0751992T3 (da) | 1994-03-08 | 2006-03-06 | Human Genome Sciences Inc | Karendotelvækstfaktor 2 |
US6608182B1 (en) | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
GB9410534D0 (en) | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
DK0807124T3 (da) * | 1994-06-09 | 2006-08-28 | Licentia Oy | Monoklonalt antistof mod FLT4-receptor-tyrosinkinase og anvendelse heraf i diagnose og terapi |
US5763733A (en) | 1994-10-13 | 1998-06-09 | Enzon, Inc. | Antigen-binding fusion proteins |
WO1998033917A1 (en) | 1994-11-14 | 1998-08-06 | The Ludwig Institute For Cancer Research | Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof |
US6645933B1 (en) * | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
ATE242809T1 (de) | 1995-09-08 | 2003-06-15 | Genentech Inc | Vegf-verwandtes protein |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
AU3968597A (en) * | 1996-08-02 | 1998-02-25 | Children's Medical Center Corporation | Method of regulating the female reproductive system through angiogenesis inhibitors |
ES2251740T3 (es) | 1996-08-23 | 2006-05-01 | Ludwig Institute For Cancer Research | Factor de crecimiento de celulas de endotelio vascular d recombinante (vegf-d). |
CA2315977A1 (en) | 1997-12-24 | 1999-07-08 | Ludwig Institute For Cancer Research | Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas |
DE69942981D1 (de) * | 1998-10-09 | 2011-01-05 | Vegenics Ltd | Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie |
KR101681886B1 (ko) | 2015-04-06 | 2016-12-12 | 서울대학교산학협력단 | 지르코니아 결합능을 가지는 펩타이드 |
-
1999
- 1999-10-08 DE DE69942981T patent/DE69942981D1/de not_active Expired - Lifetime
- 1999-10-08 NZ NZ511408A patent/NZ511408A/en unknown
- 1999-10-08 NZ NZ529063A patent/NZ529063A/en unknown
- 1999-10-08 CN CNB998142859A patent/CN100340291C/zh not_active Expired - Fee Related
- 1999-10-08 AT AT99956525T patent/ATE489108T1/de active
- 1999-10-08 AU AU13121/00A patent/AU774266B2/en not_active Ceased
- 1999-10-08 WO PCT/US1999/023525 patent/WO2000021560A1/en active IP Right Grant
- 1999-10-08 DK DK99956525.2T patent/DK1119371T3/da active
- 1999-10-08 CA CA2345276A patent/CA2345276C/en not_active Expired - Fee Related
- 1999-10-08 JP JP2000575533A patent/JP4841724B2/ja not_active Expired - Fee Related
- 1999-10-08 ES ES99956525T patent/ES2357406T3/es not_active Expired - Lifetime
- 1999-10-08 EP EP99956525A patent/EP1119371B1/en not_active Expired - Lifetime
-
2001
- 2001-04-06 NO NO20011759A patent/NO20011759L/no unknown
-
2004
- 2004-09-03 AU AU2004208675A patent/AU2004208675B2/en not_active Ceased
-
2010
- 2010-02-17 US US12/707,423 patent/US8444957B2/en not_active Expired - Fee Related
-
2011
- 2011-01-04 JP JP2011000273A patent/JP5784310B2/ja not_active Expired - Lifetime
- 2011-08-17 JP JP2011178553A patent/JP5642637B2/ja not_active Expired - Fee Related
-
2013
- 2013-04-18 US US13/865,711 patent/US20140072511A1/en not_active Abandoned
- 2013-05-07 JP JP2013097900A patent/JP2013209382A/ja active Pending
-
2014
- 2014-10-01 US US14/504,028 patent/US20150158928A1/en not_active Abandoned
-
2015
- 2015-04-06 JP JP2015077656A patent/JP2015157829A/ja active Pending
- 2015-12-29 US US14/982,422 patent/US20160184405A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012019790A5 (ja) | ||
JP2011121957A5 (ja) | ||
Kol et al. | HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting | |
Bensch et al. | 89Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment in patients with solid tumors | |
HRP20192347T1 (hr) | Antitijela prema klaudinu 18.2 koja su korisna u dijagnozi tumora | |
Wang et al. | Microarray based screening of peptide nano probes for HER2 positive tumor | |
JP2015533788A5 (ja) | ||
Peng et al. | Peptide-functionalized nanomaterials for the efficient isolation of HER2-positive circulating tumor cells | |
HRP20230237T1 (hr) | Anti-psma antitijela, bispecifične molekule za vezanje antigena koje vežu psma i cd3, i njihova uporaba | |
AU2015318207B2 (en) | Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer | |
JP2018515474A5 (ja) | ||
Silini et al. | Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor’s proangiogenic microenvironment | |
JP2013539468A5 (ja) | ||
JP2014523401A5 (ja) | ||
AU2016333538A1 (en) | GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers | |
JP2017520763A5 (ja) | ||
JP2009539082A5 (ja) | ||
JP2011509079A5 (ja) | ||
JP2018516244A5 (ja) | ||
Zhou et al. | The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models | |
WO2014205342A4 (en) | Methods for treatment of ovarian cancer | |
Lynce et al. | Pertuzumab for the treatment of breast cancer | |
JP2012531612A5 (ja) | ||
WO2024056075A1 (zh) | 盘状结构域受体2在诊断胶质瘤中的应用及相关的计算机可读介质 | |
EP3304086B1 (en) | Method for predicting responsiveness to a combination therapy with lenvatinib and everolimus |